Form 4: Dynavax Technologies Director Emilio Emini Acquires Stock Options and Restricted Stock Units

Director Emilio Emini acquired stock options and restricted stock units in Dynavax Technologies Corp on February 3, 2025.

Summary

• On February 3, 2025, Emilio Emini, a director of Dynavax Technologies Corp, was granted stock options and restricted stock units (RSUs).
• Emini acquired 42,750 stock options with an exercise price of $12.94.
• These options vest over three years, with 1/3 vesting annually starting February 3, 2025, contingent on continued service to the company.
• Emini also acquired 8,636 RSUs, each representing a contingent right to receive one share of common stock.
• The RSUs also vest over three years, with 1/3 vesting annually starting February 3, 2025, contingent on continued service.
• The release of RSU shares will be mandatorily deferred until Emini no longer provides services to the company.
• Following these transactions, Emini directly owns 42,750 stock options and 8,636 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the company's future performance. The vesting schedule encourages long-term commitment from the director.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service to the company over the next three years.

Future Outlook

The vesting of the stock options and RSUs is contingent upon the reporting person's continued service to the company.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Moderna and BioNTech also utilize stock options and RSUs as part of their executive compensation plans to incentivize performance and retain key personnel.
• The vesting schedule of three years is also a common practice, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.
• Employees may view the grant as a positive sign, indicating the company's commitment to incentivizing key personnel.

Key Dates

Keywords

Dynavax Technologies, DVAX, Form 4, Stock Options, Restricted Stock Units, Director, Emilio Emini, Beneficial Ownership, Vesting